|8.37|| +0.01 / +0.12%|
Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on discovering, acquiring, developing and commercializing proprietary therapeutics that target cancer stem cells. It currently developing two clinical stage products: SL-401 and SL-701, as well as a pipeline of preclinical candidates that include SL-801. The SL-401 is a targeted therapy directed to the interleukin-3 receptor, or IL-3R, present on CSCs and tumor bulk of a variety of hematologic cancers. The SL-701 is an enhanced immunotherapy designed to activate the immune system to attack tumors. Stemline Therapeutics was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY.
|Ivan Bergstein||Chairman, President & Chief Executive Officer|
|Kenneth Hoberman||Chief Operating Officer & Secretary|
|David G. Gionco||Chief Accounting Officer & Vice President-Finance|
|Michael Szarek||Head-Clinical & Regulatory Affairs|
|Christopher L. Brooks||Director-Preclinical Development|